Research Article
Clinical Nomogram to Predict Major Adverse Cardiac Events in Acute Myocardial Infarction Patients within 1 Year of Percutaneous Coronary Intervention
Table 1
Characteristics of the patients.
| | Variables | Subjects without MACEs | Subjects with MACEs | P value |
| | Age, year | | | <0.001 | | Gender (, %) | | | 0.538 | | Male | 216 (38.50%) | 154 (36.58%) | | | Female | 345 (61.50%) | 267 (63.42%) | | | Smoking (, %) | | | 0.334 | | No | 337 (60.07%) | 240 (57.01%) | | | Yes | 224 (39.93%) | 181 (42.99%) | | | Drinking (, %) | | | 0.362 | | No | 283 (50.45%) | 200 (47.51%) | | | Yes | 278 (49.55%) | 221 (52.49%) | | | Hypertension (, %) | | | 0.979 | | No | 211 (37.61%) | 158 (37.53%) | | | Yes | 350 (62.39%) | 263 (62.47%) | | | Diabetes mellitus (, %) | | | 0.003 | | No | 452 (80.57%) | 305 (72.45%) | | | Yes | 109 (19.43%) | 116 (27.55%) | | | History of CHD (, %) | | | 0.854 | | No | 555 (98.93%) | 417 (99.05%) | | | Yes | 6 (1.07%) | 4 (0.95%) | | | History of cerebral infarction (, %) | | | 0.244 | | No | 499 (88.95%) | 384 (91.21%) | | | Yes | 62 (11.05%) | 37 (8.79%) | | | History of dyslipidemia (, %) | | | 0.773 | | No | 559 (99.64%) | 419 (99.52%) | | | Yes | 2 (0.36%) | 2 (0.48%) | | | AMI classification (, %) | | | 0.46 | | STEMI | 328 (58.47%) | 256 (60.81%) | | | NSTEMI | 233 (41.53%) | 165 (39.19%) | | | BMI (kg/m2) | | | 0.554 | | WBC (×109/L) | | | 0.348 | | Hemoglobin | | | 0.814 | | Neutrophil granulocyte (×109/L) | | | 0.321 | | Lymphocyte (×109/L) | | | 0.860 | | hs-CRP (mg/L) | | | 0.908 | | FBG (mmol/L) | | | 0.201 | | Glycosylated hemoglobin (%) | | | 0.881 | | Total cholesterol (mmol/L) | | | 0.585 | | Triglycerides (mmol/L) | | | 0.767 | | HDL-C (mmol/L) | | | 0.361 | | LDL-C (mmol/L) | | | <0.001 | | LP(a) (mg/L) | | | <0.001 | | Uric acid (μmol/L) | | | <0.001 | | Creatinine (μmol/L) | | | 0.011 | | LDH (U/L) | | | 0.533 | | CK (U/L) | | | 0. 206 | | CK-MB (ng/mL) | | | 0.192 | | hsTnT (ng/L) | | | <0.001 | | NT-proBNP (pg/mL) | | | 0.006 | | LVEF (%) | | | <0.001 | | Syntax score | | | <0.001 | | DAPT (, %) | | | 0.193 | | No | 33 (5.88%) | 17 (4.04%) | | | Yes | 528 (94.12%) | 404 (95.96%) | | | ACE inhibitor (, %) | | | 0.365 | | No | 32 (5.70%) | 30 (7.13%) | | | Yes | 529 (94.30%) | 391 (92.87%) | | | Beta blocker (, %) | | | 0.731 | | No | 33 (5.88%) | 27 (6.41%) | | | Yes | 528 (94.12%) | 394 (93.59%) | | | Statin (, %) | | | 0.621 | | No | 33 (5.88%) | 28 (6.65%) | | | Yes | 528 (94.12%) | 393 (93.35%) | | | Bile acid level (μmol/L) | | | 0.008 |
|
|
Abbreviations: MACEs: major adverse cardiovascular events; CHD: coronary heart disease; BMI: body mass index; WBC: white blood cell; FBG: fasting blood glucose; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; LP(a): lipoprotein (a); WBC: white blood cell; LDH: lactate dehydrogenase; CK: creatine kinase; LVEF: left ventricular ejection fraction; CK-MB: creatine kinase-MB; hsTnT: hypersensitive troponin T; NT-proBNP: N-terminal probrain natriuretic peptide; ACE: angiotensin-converting enzyme; DAPT: dual antiplatelet therapy; Syntax: synergy between percutaneous coronary intervention.
|
